Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

astrocytoma/illamående

Länken sparas på Urklipp
Sida 1 från 121 resultat

Optic nerve glioma and cerebellar astrocytoma in a patient with von Recklinghausen's neurofibromatosis.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A 2 and a half year-old boy with neurofibromatosis developed unilateral proptosis, decreased visual acuity, and optic disk edema. After the discovery and removal of an optic nerve glioma, the patient had ten years of excellent health until he began having headaches, nausea, and vomiting. He had
OBJECTIVE To investigate feasibility, activity and toxicity of pre-irradiation chemotherapy (CHT) in patients with newly diagnosed high-grade astrocytoma. METHODS Thirty-five patients with glioblastoma multiform (GBM) and ten patients with anaplastic astrocytoma (AA) entered into this study. Three
BOPP chemotherapy regimen was introduced in patients with high-grade astrocytoma after surgery and radiotherapy. There were 10 anaplastic astrocytomas and 19 multiforme glioblastomas. Protocol consisted of BCNU 50 mg/m2, days 1-3, Vincristine 1,4 mg/m2 (max 2 mg), day 1, Procarbazine 50 mg/m2, days

Concomitant chemoradiotherapy for incompletely resected supratentorial low-grade astrocytoma in children: preliminary report.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND In incompletely resected low-grade supratentorial astrocytoma, long-term survival is poor; the effect of any additional treatment to surgery still remains poorly defined. The aim of this study was to evaluate the response, the survival, and the benefit of concomitant chemoradiotherapy in
The efficacy and safety of temozolomide were evaluated in 32 patients with anaplastic astrocytoma at first relapse. Temozolomide was administered orally once daily for the first five days of a 28-day cycle, at a dose of 150 or 200 mg/m(2)/day. The response rate determined by independent central
Nineteen patients with biopsy-proven high-grade astrocytomas received as initial treatment whole-brain radiation and combination chemotherapy with 5-fluorouracil (5-FU), 1,000 mg/m2/24 h as a continuous infusion for 96 h, and bolus cisdiamminedichloroplatinum II (CDDP), 100 mg/m2. Chemotherapy

Phase II study of weekly intravenous menogaril in the treatment of recurrent astrocytomas in adults.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Twenty patients with astrocytomas recurrent after surgery +/- radiation were treated on a phase II protocol of the new anthracycline derivative menogaril 115 mg/m2 administered intravenously once per week. Sixteen patients were evaluable for treatment efficacy. No patient achieved a major

Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS). METHODS Forty patients (27 men and 13 women) ages 17 to 58 years (median age, 38
BACKGROUND Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT). However, the optimal schedule of administration is unknown. METHODS In the present study, a total of 45 HGAT patients, 38 with glioblastoma multiforme (GBM) and

Temozolomide and anaplastic astrocytoma: new indication. No clear proof of efficacy.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
(1) Temozolomide, a cytotoxic agent, was recently licensed in France for treating patients with anaplastic astrocytoma who are in relapse or progression after standard therapy. (2) The clinical dossier contains only one non comparative trial. (3) In this trial, 111 patients with anaplastic

Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Nineteen assessable patients with recurrent malignant astrocytomas who had failed standard therapy (surgery, radiation, and/or chemotherapy) were treated on a phase I-II trial with a biologic extract of Serratia marcescens (ImuVert; Cell Technology, Boulder, CO) a new biologic response modifier
This patient presented with a rare case of metachronous, multicentric gliomas first manifesting as headache and nausea in 1983 when he was an 8-year-old boy. Computed tomography revealed a cerebellar tumor and the tumor was subtotally resected. The histological diagnosis was pilocytic astrocytoma,

Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The authors report the case of a 14-year-old male with a subependymal giant cell astrocytoma (SEGA) that occurred in the absence of tuberous sclerosis complex (TSC). The patient presented with progressive headache and the sudden onset of nausea and vomiting. Neuroimaging revealed an enhancing left

Treatment of astrocytoma with a 5-day cisplatin infusion.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Although cisplatin may have intrinsic activity against astrocytoma, limited penetration into the central nervous system may severely curtail delivery of adequate amounts of drug to the tumor. In an attempt to increase the dose of delivered drug without markedly increasing toxicity, cisplatin was

High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma. The present study is an open randomized clinical trial comparing estramustine phosphate (Estracyt) in addition to radiotherapy with radiotherapy alone as first
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge